Detailed narrative
Myqorzo U.S. Commercial Launch and Early Momentum
Following FDA approval in December 2025, Cytokinetics initiated a disciplined U.S. commercial launch for Myqorzo. Early indicators show strong engagement, with over 700 HCPs REM-certified within three weeks and patients receiving therapy within the first week of availability. The company launched patient and HCP marketing campaigns, established customer support systems, and hosted a national speaker broadcast. Market research indicates approximately 90% HCP awareness and intent to prescribe, driven by Myqorzo's clinical profile, flexible dosing, adaptable monitoring, and differentiated REMS program.
International Expansion and Commercial Readiness
Myqorzo received approvals in China and the EU, marking Cytokinetics' transition to a global commercial-stage company. The first European launch is planned for Germany in Q2 2026, with medical and commercial teams already hired. Country leads are in place for all EU4 countries and the U.K. to prepare for subsequent European launches in late 2026 and 2027. Health Canada also accepted the new drug submission for aficamten, with potential approval later in 2026. Sanofi is commercializing Myqorzo in China.
ACACIA-HCM Trial Update and Significance
The pivotal Phase III ACACIA-HCM trial for aficamten in non-obstructive HCM (nHCM) remains on track for top-line results in Q2 2026. nHCM represents a significant unmet medical need with no approved therapies. The trial is designed to be positive if it hits either or both of its co-primary endpoints (KCCQ and peak VO2), which are considered equally important. Management emphasized that while statistical significance is key, the magnitude of change must also be clinically meaningful, especially for KCCQ.
MAPLE-HCM sNDA and Label Expansion Potential
Cytokinetics submitted a supplemental NDA (sNDA) for MAPLE-HCM to the FDA in Q1 2026, with a conclusion expected in Q4 2026. The potential inclusion of MAPLE-HCM results in an expanded label for Myqorzo could boost category penetration, depth, and breadth, allowing more patients to benefit. Data from MAPLE-HCM, presented in Q4 2025, showed significantly more patients on aficamten achieved a positive or complete response compared to metoprolol, with improvements in symptoms and cardiac biomarkers.
Broader Pipeline Progress in Heart Failure
Beyond HCM, Cytokinetics continues to advance its heart failure pipeline. The confirmatory Phase III Code-HF trial for omecamtiv mecarbil in symptomatic heart failure with reduced ejection fraction (HFrEF) is ongoing, with 100% of U.S. sites and over 90% of European sites activated, and planned expansion into China. Enrollment for Cohort 1 of the AMBER-HFpEF Phase II trial for ulicamten in heart failure with preserved ejection fraction (HFpEF) is expected to complete in Q1 2026, with Cohort 2 enrollment by end of 2026, contingent on an interim safety review.
Financial Performance and Capital Allocation
The company reported total revenues of $17.8 million in Q4 2025 and $88 million for the full year 2025, benefiting from a $52.4 million technology transfer to Bayer and $15 million in Myqorzo approval milestones. R&D expenses increased to $416 million for FY25, and G&A expenses rose to $284.3 million due to clinical trial advancements, personnel costs, and commercial readiness investments. The company ended 2025 with $1.22 billion in cash and investments, including $100 million from a Royalty Pharma loan, and outlined capital allocation priorities focused on Myqorzo launch, pipeline advancement, and muscle biology platform investments.